Cristina Mata Fernández1, Nacho Gutierrez Carrasco2, Antonio Juan Ribelles3, Nadia Hindi Muñiz4, Anna Estival González5, Alba Rubio San Simón6, Lucía Castillo Portellano7, Sofía Ruiz Medina8, Claudia Valverde Morales9. 1. Hospital Universitario Materno Infantil Gregorio Marañón. Pediatric and Adolescent Oncohematology Unit, Madrid, Spain. cristina.mata@salud.madrid.org. 2. Hospital Universitario Virgen del Rocío, Sevilla, Spain. 3. Hospital Universitario y Politécnico La Fe, Valencia, Spain. 4. Hospital Fundación Jiménez Díaz , Madrid, Spain. 5. Instituto Catalán de Oncología, ICO. , Badalona, Spain. 6. Hospital Infantil Niño Jesús, Madrid, Spain. 7. Hospital Virgen de las Nieves, Granada, Spain. 8. Hospital Universitario Virgen de la Victoria, Málaga, Spain. 9. Hospital Universitario Vall d´Hebron, Barcelona, Spain.
Abstract
INTRODUCTION: We aimed to analyse health care services for adolescents and young adults (AYA) with sarcomas in Spain. METHODS: A survey was sent to all Spanish cancer centres, including questions about demographic, facilities, and treatment strategies for AYAs with sarcomas in the last 2 years. RESULTS: Thirty-five units participated in the survey, 17 paediatric and 15 adult units. There were three specialized AYA units. First line regimen varied depending on whether the treating unit was paediatric or not, for osteosarcomas, rhabdomyosarcomas, and non-rhabdomyosarcomas. By contrast, 91.4% of Ewing sarcomas were treated according to EE2012. In the relapse setting, differences between units were higher in all tumours. Additionally, 48% of the units reported not having trials for this population. CONCLUSION: There are major differences in the treatment of AYAs with sarcomas between adult and paediatric units. Enormous efforts are needed to homogenize treatments and increase the access to innovation.
INTRODUCTION: We aimed to analyse health care services for adolescents and young adults (AYA) with sarcomas in Spain. METHODS: A survey was sent to all Spanish cancer centres, including questions about demographic, facilities, and treatment strategies for AYAs with sarcomas in the last 2 years. RESULTS: Thirty-five units participated in the survey, 17 paediatric and 15 adult units. There were three specialized AYA units. First line regimen varied depending on whether the treating unit was paediatric or not, for osteosarcomas, rhabdomyosarcomas, and non-rhabdomyosarcomas. By contrast, 91.4% of Ewing sarcomas were treated according to EE2012. In the relapse setting, differences between units were higher in all tumours. Additionally, 48% of the units reported not having trials for this population. CONCLUSION: There are major differences in the treatment of AYAs with sarcomas between adult and paediatric units. Enormous efforts are needed to homogenize treatments and increase the access to innovation.
Authors: A Ferrari; D Stark; F A Peccatori; L Fern; V Laurence; N Gaspar; I Bozovic-Spasojevic; O Smith; J De Munter; K Derwich; L Hjorth; W T A van der Graaf; L Soanes; S Jezdic; A Blondeel; S Bielack; J-Y Douillard; G Mountzios; E Saloustros Journal: ESMO Open Date: 2021-04